Project Inform Perspectives 35 - January, 2003

In fall of 2001, the drug tenofovir (Viread) was approved based on data showing its effectiveness in people who had previously developed resistance to one or more of the older anti-HIV drugs of the NRTI class (nucleoside analogue reverse transcriptase inhibitors, such as AZT, ddI, 3TC, d4T, etc.). The drug filled an important niche since tens of thousands of people had been on such drugs for many years already. Since tenofovir also offered the advantage of once daily usage and an excellent side effect record, many people wondered how the drug would fare when used as a person's first therapy or in the early years of treatment. They didn't have long to wait for an answer, which was announced at the Barcelona Conference.

In a newly presented study, tenofovir was compared to the use of d4T (stavudine, Zerit). All 600 volunteers received efavirenz (Sustiva) and 3TC (lamivudine, Epivir) in addition to either d4T or tenofovir. The outcome was very good in both groups (Table 1).

Since three-drug combinations using d4T have long been recommended for first-time treatment use, and these data show tenofovir to be at least its equal, tenofovir will now be used for initial therapy and not just as a salvage drug for people with resistance to NRTI drugs.

Although both groups achieved almost identical suppression of HIV, there were a number of important differences. The group receiving tenofovir showed little change in triglyceride and cholesterol levels, while the group receiving d4T experienced a more pronounced rise. Increased triglyceride and cholesterol levels are believed to be associated with increased risk of fat distribution problems, diabetes and heart disease. The level of increase seen here from d4T, however, is not by itself large enough to create a serious increase in the risk of these problems. Protease inhibitors and even some non-nucleoside drugs, including efavirenz, also can increase these levels, which may be why some increase is seen in both groups in the study. These side effects, however, are consistently worse in the group receiving d4T.

d4T has also frequently been suspected of being a major contributor to mitochondrial toxicity. Mitochondria are the critical energy source of cells. Laboratory tests have shown that d4T may inhibit production of mitochondria more than other drugs of its type. Many researchers believe that mitochondrial toxicity, which is not normally tested for, is a factor in the development of such side effects as lactic acidosis, peripheral neuropathy and pancreatitis. Moreover, some preliminary findings suggest that it contributes to increases seen in total cholesterol and triglycerides and the side effects associated with these changes (lipodystrophy, diabetes, heart disease). In a further analysis of the new tenofovir study, Johns Hopkins University researcher Joe Gallant showed that people assigned to use d4T showed evidence of substantial mitochondrial damage, while those receiving tenofovir did not. So far, tenofovir has not been associated with mitochondrial toxicity in either laboratory or human studies. A summary of these findings from the study is shown in Table 2.

While some of these outcomes may also be affected by the other drugs used, the effect of the other drugs should be the same in each group since the same other drugs were used in each group. These numbers reflect the genuine differences between d4T and tenofovir. (For more information on Mitochondrial Toxicity, call the Project Inform hotline. For more information on d4T side effects, see New Questions about an Old Combination.)

Given these interesting findings, tenofovir is rapidly becoming a favored drug among many doctors and their patients. Additional studies of tenofovir are being planned or are underway including new comparative regimens, simplified treatment maintenance, prevention of mother-to-child transmission and pre-exposure prevention in high-risk populations.

It is less clear where these new findings leave d4T. Accumulating evidence seems to suggest that it is disproportionately associated with a number of recently identified side effects. While it remains a potent drug, potency alone is no longer enough to justify its widespread use. The availability of new and less troublesome drugs such as tenofovir suggests that it may be time to retire d4T to less a prominent role in the treatment of HIV.

030101
PI030107

©2003. This document is copyrighted by Project Inform, 205 13th Street, #2001, San Francisco, CA 94103. Treatment Hotline: 800-822-7422 (toll-free) or 415-558-9051 (in the San Francisco Bay Area and internationally) All Project Inform materials may be reprinted and/or distributed without prior permission. However, reprints may not be edited and must include the following text: "From Project Inform, for more information contact the Project Inform National HIV/AIDS Treatment Hotline, 800-822-7422." For permission to edit any Project Inform material for further publication, contact David Evans at the Project Inform office.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1985, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS , or the party credited as the provider of the content.